Literature DB >> 30732713

Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis.

Edward A El-Am1, Angela Dispenzieri2, Rowlens M Melduni3, Naser M Ammash3, Roger D White4, David O Hodge5, Peter A Noseworthy3, Grace Lin3, Sorin V Pislaru3, Alexander C Egbe3, Martha Grogan6, Vuyisile T Nkomo7.   

Abstract

BACKGROUND: Arrhythmias, conduction abnormalities, and intracardiac thrombus are common in patients with cardiac amyloidosis (CA). Outcomes of direct-current cardioversion (DCCV) for atrial arrhythmias in patients with CA are unknown.
OBJECTIVES: This study sought to examine DCCV procedural outcomes in patients with CA.
METHODS: Patients with CA scheduled for DCCV for atrial arrhythmias from January 2000 through December 2012 were identified and matched 2:1 with control patients by age, sex, type of atrial arrhythmia, and date of DCCV.
RESULTS: CA patients (n = 58, mean age 69 ± 9 years, 81% male) were included. CA patients had a significantly higher cardioversion cancellation rate (28% vs. 7%; p < 0.001) compared with control patients, mainly due to intracardiac thrombus identified on transesophageal echocardiogram (13 of 16 [81%] vs. 2 of 8 [25%]; p = 0.02); 4 of 13 of the CA patients (31%) with intracardiac thrombus on transesophageal echocardiogram received adequate anticoagulation ≥3 weeks and another 2 of 13 (15%) had arrhythmia duration <48 h. DCCV success rate (90% vs. 94%; p = 0.4) was not different. Procedural complications were more frequent in CA versus control patients (6 of 42 [14%] vs. 2 of 106 [2%]; p = 0.007); complications in CA included ventricular arrhythmias in 2 and severe bradyarrhythmias requiring pacemaker implantation in 2. The only complication in the control group was self-limited bradyarrhythmias.
CONCLUSIONS: Patients with CA undergoing DCCV had a significantly high cancellation rate mainly due to a high incidence of intracardiac thrombus even among patients who received adequate anticoagulation. Although the success rate of restoring sinus rhythm was high, tachyarrhythmias and bradyarrhythmias complicating DCCV were significantly more frequent in CA patients compared with control patients.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  atrial arrhythmia; atrial fibrillation; cardiac amyloidosis; cardioversion; intracardiac thrombus; transesophageal echocardiogram

Mesh:

Year:  2019        PMID: 30732713      PMCID: PMC6378685          DOI: 10.1016/j.jacc.2018.10.079

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  35 in total

1.  Predictors of unsuccessful electrical cardioversion in atrial fibrillation.

Authors:  Abdou Elhendy; Federico Gentile; Bijoy K Khandheria; Stephen C Hammill; Bernard J Gersh; Kent R Bailey; Samantha Montgomery; Kelli Burger; James B Seward
Journal:  Am J Cardiol       Date:  2002-01-01       Impact factor: 2.778

2.  Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement.

Authors:  Blaithnead Murtagh; Stephen C Hammill; Morie A Gertz; Robert A Kyle; A Jamil Tajik; Martha Grogan
Journal:  Am J Cardiol       Date:  2005-02-15       Impact factor: 2.778

Review 3.  Immunoglobulin light chain amyloidosis.

Authors:  Giampaolo Merlini; Raymond L Comenzo; David C Seldin; Ashutosh Wechalekar; Morie A Gertz
Journal:  Expert Rev Hematol       Date:  2013-12-18       Impact factor: 2.929

Review 4.  Inherited Structural Heart Diseases With Potential Atrial Fibrillation Occurrence.

Authors:  Roberta Manuguerra; Sergio Callegari; Domenico Corradi
Journal:  J Cardiovasc Electrophysiol       Date:  2015-12-18

5.  Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation.

Authors:  Christoph Röcken; Brigitte Peters; Gina Juenemann; Wolfgang Saeger; Helmut U Klein; Christof Huth; Albert Roessner; Andreas Goette
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

6.  Outcome of direct current cardioversion for atrial arrhythmias in adults with congenital heart disease.

Authors:  Naser M Ammash; Sabrina D Phillips; David O Hodge; Heidi M Connolly; Martha A Grogan; Paul A Friedman; Carole A Warnes; Samuel J Asirvatham
Journal:  Int J Cardiol       Date:  2010-10-08       Impact factor: 4.164

7.  A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.

Authors:  Rabya H Sayed; Dominic Rogers; Fakhar Khan; Ashutosh D Wechalekar; Helen J Lachmann; Marianna Fontana; Shameem Mahmood; Sajitha Sachchithanantham; Ketna Patel; Philip N Hawkins; Carol J Whelan; Julian D Gillmore
Journal:  Eur Heart J       Date:  2014-12-29       Impact factor: 29.983

8.  Outpatient electrical cardioversion of atrial fibrillation: 8 years' experience. Analysis of shock-related arrhythmias.

Authors:  Giovanni Morani; Mariantonietta Cicoira; Laura Pozzani; Carlo Angheben; Gabriele Zanotto; Corrado Vassanelli
Journal:  Pacing Clin Electrophysiol       Date:  2009-09       Impact factor: 1.976

Review 9.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

10.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more
  23 in total

Review 1.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

Review 2.  Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies.

Authors:  Isaac B Rhea; Alexander R Lyon; Michael G Fradley
Journal:  Curr Oncol Rep       Date:  2019-04-04       Impact factor: 5.075

Review 3.  How to Image Cardiac Amyloidosis: A Practical Approach.

Authors:  Sharmila Dorbala; Sarah Cuddy; Rodney H Falk
Journal:  JACC Cardiovasc Imaging       Date:  2019-10-11

4.  Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.

Authors:  Marcus V Simões; Fabio Fernandes; Fabiana G Marcondes-Braga; Philip Scheinberg; Edileide de Barros Correia; Luis Eduardo P Rohde; Fernando Bacal; Silvia Marinho Martins Alves; Sandrigo Mangini; Andréia Biolo; Luis Beck-da-Silva; Roberta Shcolnik Szor; Wilson Marques Junior; Acary Souza Bulle Oliveira; Márcia Waddington Cruz; Bruno Vaz Kerges Bueno; Ludhmila Abrahão Hajjar; Aurora Felice Castro Issa; Felix José Alvarez Ramires; Otavio Rizzi Coelho Filho; André Schmidt; Ibraim Masciarelli Francisco Pinto; Carlos Eduardo Rochitte; Marcelo Luiz Campos Vieira; Cláudio Tinoco Mesquita; Celso Dario Ramos; José Soares-Junior; Minna Moreira Dias Romano; Wilson Mathias Junior; Marcelo Iório Garcia Junior; Marcelo Westerlund Montera; Marcelo Dantas Tavares de Melo; Sandra Marques E Silva; Pedro Manoel Marques Garibaldi; Aristóteles Comte de Alencar Neto; Renato Delascio Lopes; Diane Xavier de Ávila; Denizar Viana; José Francisco Kerr Saraiva; Manoel Fernandes Canesin; Glaucia Maria Moraes de Oliveira; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2021-09       Impact factor: 2.000

Review 5.  Clinical management of amyloid cardiomyopathy.

Authors:  Morris M Kim; Clinton M Kolseth; Dayna Carlson; Ahmad Masri
Journal:  Heart Fail Rev       Date:  2021-09-01       Impact factor: 4.654

Review 6.  Amyloid and the Heart.

Authors:  Aaron M Wolfson; Kevin S Shah; Jignesh K Patel
Journal:  Curr Cardiol Rep       Date:  2019-12-03       Impact factor: 2.931

Review 7.  Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.

Authors:  Vasiliki Bistola; John Parissis; Emmanouil Foukarakis; Pipitsa N Valsamaki; Aris Anastasakis; Georgios Koutsis; Georgios Efthimiadis; Efstathios Kastritis
Journal:  Heart Fail Rev       Date:  2021-01-15       Impact factor: 4.214

8.  ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.

Authors:  Thomas H Brannagan; Michaela Auer-Grumbach; John L Berk; Chiara Briani; Vera Bril; Teresa Coelho; Thibaud Damy; Angela Dispenzieri; Brian M Drachman; Nowell Fine; Hanna K Gaggin; Morie Gertz; Julian D Gillmore; Esther Gonzalez; Mazen Hanna; David R Hurwitz; Sami L Khella; Mathew S Maurer; Jose Nativi-Nicolau; Kemi Olugemo; Luis F Quintana; Andrew M Rosen; Hartmut H Schmidt; Jacqueline Shehata; Marcia Waddington-Cruz; Carol Whelan; Frederick L Ruberg
Journal:  Orphanet J Rare Dis       Date:  2021-05-06       Impact factor: 4.123

Review 9.  Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.

Authors:  Jan M Griffin; Mathew S Maurer
Journal:  Trends Cardiovasc Med       Date:  2019-12-17       Impact factor: 6.677

Review 10.  Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Authors:  Lily K Stern; Michelle M Kittleson
Journal:  Curr Oncol Rep       Date:  2021-03-16       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.